Vision Care Group CEO Masayo Takahashi led the world's first clinical study of a retinal cell transplant derived from induced pluripotent stem cells (iPS cells) in 2014 when she led the Laboratory for Retinal Regeneration at Japan’s Riken Center for Biosystems Dynamics Research. In 2019, she founded Vision Care and subsequently founded two subsidiary companies dedicated to developing cell and gene therapies. Read More
Researchers from Broad Institute Inc. and affiliated organizations have reported data from a study that highlighted a new variant-to-gene-to-program (V2G2P) approach designed to link variants from genome-wide association studies (GWAS) to genes and identify their convergence onto specific disease-associated transcriptional programs. Read More
Medigene AG has selected initial clinical indications for its lead candidate, MDG-1015, specifically gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma. Read More
Valirx plc has signed an over-arching agreement with the University of Dundee and its drug discovery unit (DDU) to access research relating to novel therapeutic candidates. Read More
It is known that CX3C chemokine receptor 1 (CX3CR1) expressed on macrophages plays a crucial role in inner hair cell ribbon synaptic repair and spiral ganglion neuron survival after synaptopathic noise-induced trauma. Read More
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration and option agreement with Shattuck Labs Inc. to generate bifunctional fusion proteins. Read More
Arcus Biosciences Inc. has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer. Read More
Trawsfynydd Therapeutics Inc. has received approval to initiate a first-in-man phase I trial of the novel best-in-class COVID-19 treatment, TRX-01, an inhibitor targeting the SARS-CoV-2 viral main protease (3CL, Mpro). Read More
Neuroninn Biosciences Co. Ltd. has synthesized G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of anxiety disorders, depression, substance abuse and dependence and Parkinson’s disease. Read More
Jnana Therapeutics Inc. has identified sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, metabolic dysfunction-associated steatohepatitis, phenylketonuria, metabolic syndrome, obesity, neurodevelopmental and autism spectrum disorders, among others. Read More
Japanese researchers have developed a new rat model of thromboembolic ischemic stroke that did not require arterial ligation of the external carotid artery, which makes the research for thrombolytic agents more complicated. Read More
Jiangsu Tasly Diyi Pharmaceutical Co. Ltd. has divulged Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of inflammation, infection, cancer and autoimmune disease. Read More
Sutro Biopharma Inc. has described antibody-drug conjugates (ADCs) comprising a cytotoxic drug linked to an antibody or polypeptide residue through a linker reported to be useful for the diagnosis and treatment of cancer. Read More
Delsitech Ltd. and Tolmar International Ltd. have signed a global license and development agreement whereby Tolmar will obtain a global license to utilize Delsitech’s proprietary, silica-based, drug delivery technology platform for the development and commercialization of two undisclosed long-acting injectable drug products. Read More
